L3VLUP
ProSign in

ROIV · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ROIVLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ROIV
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterROIVLLY
Q3 2020none listed holders, n.a.33 holders, $14.1bn
Q4 2020none listed holders, n.a.29 holders, $17.3bn
Q1 2021none listed holders, n.a.24 holders, $23.0bn
Q2 2021none listed holders, n.a.24 holders, $27.8bn
Q3 2021none listed holders, n.a.31 holders, $29.9bn
Q4 20211 holders, $889m31 holders, $34.7bn
Q1 20221 holders, $436m24 holders, $35.3bn
Q2 20221 holders, $359m33 holders, $42.7bn
Q3 20222 holders, $292m31 holders, $43.4bn
Q4 20223 holders, $829m31 holders, $46.6bn
Q1 20236 holders, $715m33 holders, $44.3bn
Q2 20238 holders, $1.0bn37 holders, $59.6bn
Q3 20238 holders, $1.7bn44 holders, $67.6bn
Q4 20236 holders, $1.5bn45 holders, $73.6bn
Q1 20246 holders, $912m41 holders, $95.3bn
Q2 20248 holders, $1.4bn43 holders, $110bn
Q3 20248 holders, $1.4bn45 holders, $107bn
Q4 20248 holders, $1.3bn46 holders, $93.9bn
Q1 20257 holders, $1.1bn42 holders, $98.4bn
Q2 20259 holders, $1.2bn43 holders, $93.2bn
Q3 202511 holders, $1.5bn39 holders, $86.7bn
Q4 202514 holders, $1.9bn41 holders, $123bn
Q1 202614 holders, $3.3bn39 holders, $106bn
Q2 202615 holders, $4.5bn44 holders, $132bn
ROIV

Roivant Sciences LTD

Holders
14
Reported value
$3.3bn
Buyers
18
Sellers
15

Breadth +3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
39
Reported value
$106bn
Buyers
25
Sellers
25

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ROIV (6)

Farallon Capital Management LLC, Greenlight Capital, Maverick Capital Ltd, PDT Partners LLC, Viking Global Investors LP, Winton Group Ltd

Only LLY (31)

Acadian Asset Management LLC, AllianceBernstein LP, ARK Investment Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Millennium Management LLC, Neuberger Berman Group LLC, Point72 Asset Management LP, Polen Capital Management LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Soros Fund Management LLC, and 6 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →